Department of Critical Care Medicine, First Affiliated Hospital of Shenzhen University (Shenzhen Second People's Hospital), Shenzhen 518015, Guangdong, China. Corresponding author: Yao Yongming, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 May;32(5):531-536. doi: 10.3760/cma.j.cn121430-20200228-00095.
Metagenomic next generation sequencing (mNGS) is a non-targeted and broad-spectrum pathogen screening technology. In recent years, more and more studies have shown that mNGS pathogen detection plays a key role in the field of clinical severe infection, especially when the severe infection was caused by rare pathogens. However, due to its high cost and high requirements of experimental conditions, it has not been included as a routine clinical test yet. Nevertheless, it can be predicted that with the decrease of sequencing cost and the continuous improvement of medical level in China, the conditions for large-scale clinical application of pathogenic diagnosis based on mNGS have gradually matured. This consensus described the expert consensus of etiology diagnosis based on mNGS in the scope of detection, rules and applications in clinical moderate and severe infections, and also looked forward to the improvement of its clinical application in the future.
宏基因组下一代测序（mNGS）是一种非靶向、广谱的病原体筛查技术。近年来，越来越多的研究表明，mNGS病原体检测在临床严重感染领域发挥着关键作用，尤其是当严重感染由罕见病原体引起时。然而，由于其成本高且对实验条件要求高，尚未被纳入常规临床检测。尽管如此，可以预测，随着测序成本的降低以及我国医疗水平的不断提高，基于mNGS进行病原体诊断的大规模临床应用条件已逐渐成熟。本共识阐述了基于mNGS的病因诊断在临床中重度感染的检测范围、规则及应用方面的专家共识，同时也展望了其未来临床应用的改进。
